The latest update is out from Kontafarma China Holdings Ltd ( (HK:1312) ).
Kontafarma China Holdings Ltd reported its audited consolidated results for the year ended December 31, 2024, showing a revenue increase to HK$897.5 million from HK$809.1 million in 2023. Despite the revenue growth, the company experienced a net loss of HK$99 million, up from a HK$61.1 million loss the previous year, attributed to increased distribution, selling, and administrative expenses. The announcement highlights the financial challenges faced by the company, impacting its market positioning and raising concerns for stakeholders about the company’s future profitability and operational efficiency.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd is a company incorporated in the Cayman Islands, operating in industries related to pharmaceuticals and health products. The company focuses on providing a range of health-related products and services, catering to the growing demand for wellness and healthcare solutions.
YTD Price Performance: -16.67%
Average Trading Volume: 1,543,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.5M
Find detailed analytics on 1312 stock on TipRanks’ Stock Analysis page.